In contrast, excepting a small fraction of ERBC with high mutation load, immune infiltration and improved survival (15), very few studies have documented significant CD8+ T cell infiltration in most ERBC which comprise more than two thirds of all newly diagnosed breast cancers. This evidence concerns the gene CD8A and breast cancer.